A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects with Hepatitis C

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-000828-14

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary objective: - To assess the proportion of subjects in each group with undetectable plasma HCV RNA, 24 weeks after the completion of the assigned study drug regimen.


Critère d'inclusion

  • Hepatitis C virus (HCV) infection